News
Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a ...
Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...
Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split: ...
Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...
By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on ...
5don MSN
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...
Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...
The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results